Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

WQ-3810: A new fluoroquinolone with a high potential against fluoroquinolone-resistant Mycobacterium tuberculosis.

Tuberculosis (Edinburgh, Scotland) - 1 Jan 2020

Ouchi Yuki, Mukai Tetsu, Koide Kentaro, Yamaguchi Tomoyuki, Park Jong-Hoon, Kim Hyun, Yokoyama Kazumasa, Tamaru Aki, Gordon Stephen V, Nakajima Chie, Suzuki Yasuhiko

Abstract excerpt

Fluoroquinolone (FQ) resistance in Mycobacterium tuberculosis (Mtb), caused by amino acid substitutions in DNA gyrase, has been increasingly reported worldwide. WQ-3810 is a newly developed FQ that is highly active against FQ-resistant pathogens; however, its activity against Mtb has not been evaluated. Herein we examined the efficacy of WQ-3810 against Mtb through the use of recombinant Mtb DNA gyrases. In...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibiotics, Antitubercular
Share to Azetidines

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to DNA Gyrase

Share to Drug Synergism

Share to Ethambutol

Share to Fluoroquinolones

Share to Mycobacterium bovis

Share to Topoisomerase II Inhibitors

Source

Identifiers

PMID: 31778929
DOI: 10.1016/j.tube.2019.101891

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

WQ-3810: A new fluoroquinolone with a high potential against fluoroquinolone-resistant Mycobacterium tuberculosis.PMID 31778929Read ↗

Comparative in vitro susceptibility of a novel fluoroquinolone antibiotic candidate WFQ-228, levofloxacin, and moxifloxacin against Mycobacterium tuberculosis.Semantic proximity Read ↗

DNA topoisomerase I and DNA gyrase as targets for TB therapySemantic proximity Read ↗

Molecular characterization of fluoroquinolone-resistant Mycobacterium tuberculosis clinical isolates from Shanghai, China.Semantic proximity Read ↗

Extending the Definition of the GyrB Quinolone Resistance-Determining Region in Mycobacterium tuberculosis DNA Gyrase for Assessing Fluoroquinolone Resistance in M. tuberculosisSemantic proximity Read ↗

Fluoroquinolone resistance and mutational profile of gyrA in pulmonary MDR tuberculosis patients.Semantic proximity Read ↗

Fluoroquinolone resistance and mutational profile of gyrA in pulmonary MDR tuberculosis patientsSemantic proximity Read ↗

Mycobacterium tuberculosis DNA Gyrase as a Target for Drug DiscoverySemantic proximity Read ↗

Screening of Compounds for Anti-tuberculosis Activity, and in vitro and in vivo Evaluation of Potential CandidatesSemantic proximity Read ↗

Advancement of GyrB Inhibitors for Treatment of Infections Caused by Mycobacterium tuberculosis and Non-tuberculous MycobacteriaSemantic proximity Read ↗

Fluoroquinolone resistance detection in Mycobacterium tuberculosis with locked nucleic acid probe real-time PCR.Semantic proximity Read ↗

Rational Exploration of 2,4-Diaminopyrimidines as DHFR Inhibitors Active against Mycobacterium abscessus and Mycobacterium avium, Two Emerging Human PathogensSemantic proximity Read ↗

Molecular characterization of <i>Mycobacterium ulcerans</i> DNA gyrase and identification of mutations reduced susceptibility against quinolones <i>in vitro</i>Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.